BTA quantitative determination kit_Hubei Shengfeng Medical Equipment Co., Ltd.

Product Service

Location：

Homepage

/

Product page

/

Drug

/

BTA quantitative determination kit

1





Description

Product name: BTA quantitative determination kit

Specification model: 96 servings/box

Unit: Box

Product name (registered certificate name): BTA quantitative determination kit (microplate chemiluminescence method)

Supplier: Hubei Shengfeng Medical Equipment Co., Ltd.

Registration number: Registration number: National Machinery Note 20163400642

With sets of medical equipment: chemiluminescence immunoassay analyzer (LUMO type)

Registration number: Yuxie Zhuzhun 20192220574

product manual:

In order to improve the detection method of bladder cancer and provide a more convenient and worry-free diagnosis and treatment environment and experience for the majority of bladder cancer patients, the BTA quantitative determination kit (microplate chemiluminescence method) in vitro clinical examination project is hereby launched. The kit is a BTA quantitative determination kit (microplate chemiluminescence method). At present, in our department, we usually take urine samples from the middle part of natural urination for testing to avoid mandatory sudden urine samples. The method is simple and convenient. The BTA quantitative determination of bladder tumor is by collecting the urine of the tester, and detecting the BTA content in it to reflect the progress of the tumor. Bladder tumor-associated antigen (BTA), in the process of tumorigenesis and development, endogenous basal proteins secreted by tumor cells bind to the surface protein receptors of the basement membrane, and release proteolytic enzymes to destroy the basement membrane and basement. Membrane fragments enter the bladder and aggregate into a polymer compound called BTA. The higher the clinical stage and pathological grade of bladder malignant tumors, the higher the urine BTA level. For the presence and changes of early low-grade and low-stage bladder tumor cells, non-invasive imaging and invasive cystoscopy are difficult to detect with the naked eye. However, the quantitative measurement of bladder tumor BTA has high sensitivity and unique advantages. Combined imaging detection and cystoscopy can greatly increase the detection probability of early bladder tumors, and when the test results are negative, it can basically be determined that there is no bladder tumor. It has the effect of early prevention, early detection, and early treatment on the patient's condition, and its clinical application value is very high. It adopts independent research and development of patented specific antibody technology, which can better meet the physical needs of the domestic population. The sample is easy to collect, and only 5μL of urine is required to complete the test, avoiding cross-infection; obtaining results quickly, one-step operation, rapid batch detection of results, providing a new, non-invasive, accurate, and in vitro bladder tumor detection for clinics Methods to increase patient compliance. Compared with traditional "urine cytology", it is more sensitive and can detect or rule out bladder tumors earlier;

Compared with "cystoscopy", it is more green and non-invasive, and easier to detect early bladder tumors; it can be used as an early screening for high-risk groups;

It can be used for treatment effect evaluation and postoperative follow-up detection; it can be combined with cystoscopy for diagnosis of primary tumors and screening of high-risk populations.

The specimen is urine, the diagnosis method is simple and reliable, the sensitivity and specificity are high, which greatly improves the accuracy of clinical diagnosis of chronic prostatitis and provides patients with more physical services.